How specific proteins shape face and skull development
Official title: Functional Characterization of Mediator Complex Proteins in Neural Crest and Craniofacial Development
Funded at State University of New York at Albany · NIH-11161165 · Data updated 2026-11-12
This project explores how certain proteins guide the development of the face and skull, aiming to understand conditions like cleft palate and a smaller lower jaw.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | State University of New York at Albany NIH-funded |
| Lab location | 1 site (Albany, United States) |
| Project start | September 12, 2023 |
| Project end | August 31, 2026 |
| Funding year | 2025 |
| Award (this year) | $244,597 |
| NIH project number | 5R00DE030972-05 |
| Project ID | NIH-11161165 on NIH RePORTER |
Who could benefit from this research
✓Could help
Patients with craniofacial developmental disorders, such as cleft palate, retrognathia, or conditions like 22q11 deletion syndrome, could benefit from the knowledge gained from this work.
✕Less likely to help
Patients seeking immediate treatment or direct clinical intervention will not find direct benefit from this foundational laboratory-based research.
What this research studies
Craniofacial developmental disorders, such as cleft palate and a smaller lower jaw (retrognathia), are common and often result from issues with special cells called neural crest cells. While we know some genetic causes for these conditions, many cases still lack a clear genetic explanation. This project focuses on a gene called Med23, which has been identified as crucial for proper face and skull development. Researchers are using models to understand how Med23 functions within neural crest cells and other cell types, and how its malfunction leads to these developmental problems. The ultimate goal is to uncover the specific roles of Med23 and related proteins to better understand the complex origins of these conditions.
Why it matters
Potential benefit: If successful, this research could lead to a deeper understanding of the genetic and cellular causes of craniofacial disorders, potentially guiding future diagnostic tools or interventions.
How similar studies have gone: While genetic links to some craniofacial conditions are known, this specific focus on the Med23 gene and its role in neural crest cell development represents a novel area of investigation.
Where this research is happening
-
State University of New York at Albany
Albany, United States Active
Researchers
- Principal investigator: Dash, Soma — State University of New York at Albany
- Study coordinator: Dash, Soma
Related research
Other NIH-funded projects on the same topics.
-
Cross-disease small molecule therapy for CAG expansion spinocerebellar ataxias
A new NIH grant is exploring whether existing and natural small molecules can lower harmful CAG RNA and proteins across several spinocerebellar ataxias to help people with these conditions.
-
New small molecule therapeutics to help myotonic dystrophy
A new NIH-funded project tests specially designed small molecules to lower harmful RNA activity in myotonic dystrophy and related diseases, aiming to reduce disease-driving RNA effects.
-
Biofilm structure and its role in the start of gum disease
A researchers team will study how tiny communities of bacteria at the gumline interact with the mouth’s tissues to spark inflammation that leads from healthy gums to periodontal disease.
-
Understanding how unusual RNA translation happens in neurological diseases
Researchers are studying how RNAs can start making proteins in unexpected ways in neurodegenerative diseases, which could reveal new targets for therapy.
-
Early-life neighborhood redlining and lifetime mortality in a historical cohort
This project looks at whether growing up in areas graded or disinvested by HOLC in the 1930s affects mortality later in life for people born in 1930–1940.
-
Activating PTP1B and Other Phosphatases with Small Molecules
A safety-focused, patient-friendly look at a project that aims to turn on natural enzymes in our cells to help correct harmful signals in diseases.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.